MSD International GmbH (Singapore Branch) – FDA 483, Sep 3, 2021
MSD International GmbH Singapore Branch, a sterile drug product manufacturer in Singapore, was cited for significant deficiencies during an FDA inspection. Observations included failures in aseptic processing procedures, lack of assurance in manufacturing process consistency, inadequate written procedures for foreign matter investigation, and insufficient verification of supplier COAs. Additionally, the facility exhibited design and maintenance issues, posing risks to product quality and sterility.
ID · 61654fcd-a8cd-4a95-99b8-a4a44ce2cf88
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.